Eris Lifesciences Promoter Group Declares 53.92% Stake and No New Encumbrances as of March 31, 2026
Eris Lifesciences Promoter Group, represented by Kaushal Kamlesh Shah, declared holding 7,47,08,744 equity shares (53.92%) as of March 31, 2026. No new encumbrances were made during the financial year, beyond previously disclosed ones.
This is a standard disclosure under SEBI regulations and does not indicate any significant change in the company's financial standing or strategic direction.
The announcement is a routine regulatory filing confirming shareholding and absence of new encumbrances. It does not contain new positive or negative financial information.
Eris Lifesciences Limited has received a declaration from Kaushal Kamlesh Shah, a Promoter, on behalf of all Promoters and the Promoter Group. This declaration, submitted under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, confirms the holding of 7,47,08,744 equity shares, representing approximately 53.92% of the total equity, as of March 31, 2026.
Furthermore, the declaration explicitly states that no encumbrances, either direct or indirect, have been made during the financial year ended March 31, 2026, beyond those already disclosed. The company has been requested to update its records accordingly.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under shareholding pattern. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.